Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: A multicenter, prospective, observational study

Modern Rheumatology

Volumn 23, Issue 6, 2013, Pages 1076-1084

  Hasegawa, Minoru ^a   Asano, Yoshihide ^b   Endo, Hirahito ^c   Fujimoto, Manabu ^a   Goto, Daisuke ^d   Ihn, Hironobu ^e   Inoue, Katsumi ^f   Ishikawa, Osamu ^g   Kawaguchi, Yasushi ^h   Kuwana, Masataka ⁱ   Ogawa, Fumihide ^j   Takahashi, Hiroki ^k   Tanaka, Sumiaki ^l   Sato, Shinichi ^b   Takehara, Kazuhiko ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^g GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁱ KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^k SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chemokine; CXCL8; HAQ; Serum marker; Systemic sclerosis

Indexed keywords

ADOLESCENT; ADULT; AGED; CHEMOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84894379287     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0795-6     Document Type: Article

References (43)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19): 1989-2003.
2. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2012;8(1): 42-54.
3. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum. 1984;27(6): 645-53.
4. Gruschwitz M, Sepp N, Kofler H, Wick G. Expression of class IIMHC antigens in the dermis of patients with progressive systemic sclerosis. Immunobiology. 1991;182(3-4): 234-55.
5. Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol. 2003;15(6): 772-7.
6. Hasegawa M, Sato S. The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis. Front Biosci. 2008; 13: 3637-47.
7. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11): 2437-44.
8. Medsger TA Jr. Classification, purpose. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Philadelphia: Williams & Wilkins; 2004. p. 17-28.
9. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1): 35-42.
10. Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis. 2006;65(2): 209-15.
11. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009;60(10): 3098-107.
12. LeRoy EC, Krieg T, Black C, Medsger TAJ, Fleischmajer R, Rowell N, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol. 1988;15: 202-5.
13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23: 581-90.
14. Clements P, Lachenbrush P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22: 1281-5.
15. Steen VD, Powell DL, Medsger TAJ. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988;31: 196-203.
16. Kuwana M, Sato S, Kikuchi K, Kawaguchi Y, Fujisaku A, Misaki Y, et al. Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis. J Rheumatol. 2003;30(6): 1253-8.
17. Chen R, Lowe L, Wilson JD, Crowther E, Tzeggai K, Bishop JE, et al. Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin Chem. 1999;45(9): 1693-4.
18. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Eng J Med. 1998;338: 436-45.
19. Lee EB, Zhao J, Kim JY, Xiong M, Song YW. Evidence of potential interaction of chemokine genes in susceptibility to systemic sclerosis. Arthritis Rheum. 2007;56(7): 2443-8.
20. Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K, et al. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol. 2003;30(7): 1524-8.
21. Codullo V, Baldwin HM, Singh MD, Fraser AR, Wilson C, Gilmour A, et al. An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann Rheum Dis. 2011;70(6): 1115-21.
22. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther. 2009;11(5):R147.
23. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Pathobiology. 1993;61: 239-46.
24. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol. 1998;25(2): 296-301.
25. Keane MP, Arenberg DA, Lynch JP 3rd, Whyte RI, Iannettoni MD, Burdick MD, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol. 1997;159(3): 1437-43.
26. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997;40: 746-51.
27. Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther. 2009;11(4):R111.
28. Wolff B, Burns AR, Middleton J, Rot A. Endothelial cell ''memory'' of inflammatory stimulation: human venular endothelial cells store interleukin 8 in Weibel-Palade bodies. J Exp Med. 1998;188(9): 1757-62.
29. Utgaard JO, Jahnsen FL, Bakka A, Brandtzaeg P, Haraldsen G. Rapid secretion of prestored interleukin 8 from Weibel-Palade bodies of microvascular endothelial cells. J Exp Med. 1998; 188(9): 1751-6.
30. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 2001;44(11): 2665-78.
31. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000;404(6776): 407-11.
32. Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum. 2006;54(1): 214-25.
33. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem. 1996;271(30): 17779-84.
34. Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum. 2005;52(12): 3772-82.
35. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol. 1999;117(1): 159-65.
36. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford). 2008;47(1): 45-9.
37. Hasegawa M, Fujimoto M, Matsushita T, Hamaguchi Y, Takehara K, Sato S. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin Rheumatol. 2011;30(2): 231-7.
38. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003;24(1): 25-9.
39. Distler O, Rinkes B, Hohenleutner U, Scholmerich J, Landthaler M, Lang B, et al. Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis. Rheumatol Int. 1999;19(1-2): 39-46.
40. Anderegg U, Saalbach A, Haustein UF. Chemokine release from activated human dermal microvascular endothelial cells-implications for the pathophysiology of scleroderma? Arch Dermatol Res. 2000;292(7): 341-7.
41. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol. 2004;138(3): 540-6.
42. Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci. 2004;35(1): 43-51.
43. Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK 3rd, Impens AJ, et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res Ther. 2011;13(1):R18.